17:57 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Coronavirus; influenza virus; HIV/AIDS; Ebola Cell culture and rat studies identified lipopeptide-based inhibitors of MERS-CoV S protein, Ebola virus glycoprotein and HIV env that could help treat Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola...
17:57 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Antibody scaffolds Sialylation of immune complexes could enhance the response to HIV vaccines. Patients who spontaneously controlled HIV without therapy and patients who had evolved neutralizing activity against a panel of 11 HIV-1 viruses...
17:56 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms; imaging

TECHNOLOGY: Structural analyses; other An electron microscopy-based method for identifying epitopes that elicit potent neutralizing antibodies could be used to guide the development of vaccines for infectious diseases. The method involves six steps: digesting animal-...
18:33 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Patient sample and cell culture studies identified a neutralizing antibody against HIV gp120 that could help treat HIV/AIDS. Screening of peripheral blood B cells from a patient followed by testing of...
19:11 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Gilead's TLR7 agonist shows promise against HIV in shock and kill combo in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...
22:57 , Mar 5, 2018 |  BC Extra  |  Preclinical News

HIV shock and kill combo shows promise in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...
19:40 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Non-human primate studies suggest a trispecific, broadly neutralizing antibody (bNAb) could help treat HIV. Screening of combinations of a panel of bNAbs in neutralization assays, followed by generation of bNAbs incorporating features of...
00:01 , Sep 21, 2017 |  BC Extra  |  Preclinical News

NIAID, Sanofi develop trispecific bNAb for HIV

In a paper published in...
15:44 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Mologen's lefitolimod misses in extension for HIV infection

Mologen AG (Xetra:MGN) reported data from 12 patients with chronic HIV-1 infection on antiretroviral therapy (ART) in a 24-week extension of the open-label, Danish Phase Ib/IIa TEACH trial showing that twice-weekly 60 mg subcutaneous lefitolimod...
23:03 , Aug 9, 2017 |  BC Extra  |  Clinical News

Mologen sinks on lefitolimod HIV miss

Mologen AG (Xetra:MGN) dropped €0.81 (21%) to €3.06 on Wednesday after its lefitolimod (MGN1703) missed the primary endpoint in an extension of the Phase Ib/IIa TEACH trial to treat HIV infection in patients on antiretroviral...